onc Videos

Videos

Videos

Addition of Ribociclib to Nonsteroidal Aromatase Inhibitor Benefits Broad Range of Patients With HR-Positive, HER2-Negative Early Breast Cancer

11/02/2023

Featuring Aditya Bardia, MD

Aditya Bardia, MD, discusses results from a subgroup analysis of the phase 3 NATALEE study comparing invasive disease-free survival (iDFS) across a broad range of patients with HR-positive, HER2-negative early breast cancer treated with...

Aditya Bardia, MD, discusses...

11/02/2023

Oncology

Elena Castro, MD, PhD Hospital Universitario 12 de Octubre

Videos

Niraparib Plus Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer With HRR Gene Alterations

11/01/2023

Featuring Elena Castro, MD, PhD

Featuring Elena Castro, MD, PhD ...

Elena Castro, MD, shares final results from the MAGNITUDE study evaluating niraparib plus abiraterone acetate plus prednisone for patients with metastatic castration-resistant prostate cancer and HRR gene alterations.

Elena Castro, MD, shares final...

11/01/2023

Oncology

Kenneth Anderson, MD, Dana-Farber Cancer Institute

Videos

New Targets on the Horizon for Multiple Myeloma Treatment

11/01/2023

Featuring Kenneth C. Anderson, MD

Featuring Kenneth C. Anderson, MD ...

At the 2023 Lymphoma, Leukemia & Myeloma Congress, Kenneth C. Anderson, MD, discussed existing and promising novel therapies for patients with multiple myeloma.

At the 2023 Lymphoma, Leukemia &...

11/01/2023

Lymphoma, Leukemia & Myeloma Network

Antoni Vilaseca, MD, Hospital Clínic de Barcelona

Videos

Novel Erdafitinib Intravesical Delivery System Showed Safety, Efficacy for Patients With Non–Muscle-Invasive Bladder Cancer With Select FGFR Alterations

11/01/2023

Featuring Antoni Vilaseca, MD

Antoni Vilaseca, MD, discusses the novel erdafinitib delivery system for patients with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations.

Antoni Vilaseca, MD, discusses...

11/01/2023

Oncology

Videos

Mitigating Risk of Transformation Among Patients With Follicular Lymphoma

10/31/2023

Featuring Kiran Kumar, MD, MBA

Featuring Kiran Kumar, MD, MBA ...

Kiran Kumar, MD, MBA, discusses strategies for mitigating tumor burden and risk of transformation for patients with follicular lymphoma, particularly among those with early-stage or limited disease.

Kiran Kumar, MD, MBA, discusses...

10/31/2023

Oncology

Videos

Radiation Therapy for Patients With R/R Non-Hodgkin Lymphoma With Incomplete Response to CAR T-Cell Therapy

10/30/2023

Featuring Kiran Kumar, MD, MBA

Featuring Kiran Kumar, MD, MBA ...

Kiran Kumar, MD, MBA, explains study results regarding the potential benefits of re-priming radiation therapy among patients with R/R non-Hodgkin lymphoma, including FL and DLBCL, who experienced incomplete response after CD19-directed CAR...

Kiran Kumar, MD, MBA, explains...

10/30/2023

Oncology

Videos

Modifying Treatment Strategies for Patients With FL or DLBCL at Risk of Therapy-Related Transformation

10/30/2023

Featuring Abhay Singh, MD

Abhay Singh, MD, discusses the need for modifications in treatments for older patients with follicular lymphoma or DLBCL who are at risk of transformation to therapy-related myeloid neoplasms or acute myeloid leukemia.

Abhay Singh, MD, discusses the...

10/30/2023

Oncology

Henrik Grönberg, MD, PhD, Karolinska Institute

Videos

Comparing Androgen Receptor Pathway Inhibitors and Taxanes for Metastatic Castration-Resistant Prostate Cancer in a Biomarker-Driven, Outcome-Adaptive Platform Trial

10/26/2023

Featuring Henrik Grönberg, MD, PhD

Featuring Henrik Grönberg, MD, PhD ...

Henrik Grönberg, MD, PhD, shared results from the phase 3 ProBio trial which found that androgen receptor pathway inhibitors improved survival outcomes compared to both standard of care and taxanes among patients with metastatic...

Henrik Grönberg, MD, PhD, shared...

10/26/2023

Oncology

Conference Coverage

Datopotamab Deruxtecan for Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer

10/25/2023

Featuring Aditya Bardia, MD

Aditya Bardia, MD, discusses results from the TROPION-Breast01 trial comparing datopotamab deruxtecan with chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2-negative breast cancer who have previously...

Aditya Bardia, MD, discusses...

10/25/2023

Oncology

Videos

177Lu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

10/25/2023

Featuring Oliver Sartor, MD

At the 2023 ESMO Congress, Oliver Sartor, MD, described results from the phase 3 PSMAfore trial evaluating 177Lu-PSMA-617 vs androgen receptor-directed therapy for taxane-naive patients with metastatic castration-resistant prostate cancer.

At the 2023 ESMO Congress,...

10/25/2023

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology